Literature DB >> 4282933

[Virulence and immunogenicity of a modified vaccinia virus (strain MVA) (author's transl)].

V Hochstein-Mintzel, H C Huber, H Stickl.   

Abstract

Mesh：

Substances：

Year:  1972        PMID： 4282933

Source DB:  PubMed          Journal:  Z Immunitatsforsch Exp Klin Immunol        ISSN： 0300-872X


× No keyword cloud information.
  8 in total

1.  Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.

Authors:  Ann Chahroudi; David A Garber; Patrick Reeves; Luzheng Liu; Daniel Kalman; Mark B Feinberg
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  The C11R gene, which encodes the vaccinia virus growth factor, is partially responsible for MVA-induced NF-κB and ERK2 activation.

Authors:  Stefani Martin; Daniel T Harris; Joanna Shisler
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

Review 3.  Multivalent and Multipathogen Viral Vector Vaccines.

Authors:  Katharina B Lauer; Ray Borrow; Thomas J Blanchard
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

4.  Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.

Authors:  Sharon Melamed; Linda S Wyatt; Robin J Kastenmayer; Bernard Moss
Journal:  Vaccine       Date:  2013-08-06       Impact factor: 3.641

5.  Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer.

Authors:  Robert J Amato; Mika Stepankiw
Journal:  Clin Med Insights Oncol       Date:  2012-01-05

Review 6.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

Review 7.  LC16m8: an attenuated smallpox vaccine.

Authors:  Julie Kenner; Fiona Cameron; Cyril Empig; David V Jobes; Marc Gurwith
Journal:  Vaccine       Date:  2006-04-21       Impact factor: 3.641

8.  Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels.

Authors:  Naif Khalaf Alharbi; Fahad Aljamaan; Haya A Aljami; Mohammed W Alenazi; Hind Albalawi; Abdulrahman Almasoud; Fatima J Alharthi; Esam I Azhar; Tlili Barhoumi; Mohammad Bosaeed; Sarah C Gilbert; Anwar M Hashem
Journal:  Vaccines (Basel)       Date:  2022-08-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.